BioCryst Pharmaceuticals (BCRX) Trades Higher On Flu News
BioCryst (BRCX) announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S. Each partner will immediately begin meeting with key government officials in their respective territories to discuss peramivir’s availability during this global health emergency.
These included deal with moksha8 Pharmaceuticals, Inc. has established broad commercial operations in Brazil and Mexico, the two key countries in Latin America that represent 75% of the $30 billion Latin America pharmaceutical market, NT Pharma in China, and The Neopharm Group in Israel
Shares are up 9% to $11.71 on the news.
Douglas A. McIntyre
